Vitamin D Supplementation on Reported Rates of Taxane-Induced Neuropathy

• Status: Not yet recruiting
• Trial end date: 2025-03-31
• Target enrollment: 0
• Participant gender: All

Summary

This is a two-arm randomized clinical trial in which 80 participants with Vitamin D deficiency and scheduled to begin taxane-based chemotherapy will be randomized to either: 1) prescribed vitamin D replacement or 2) standard of care.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Virginia Commonwealth University
• Treatments: Cholecalciferol; Ergocalciferols; Vitamin D; Vitamins

Criteria

Inclusion Criteria:

• Diagnosis of stage I-III cancer of any type

• Scheduled to begin taxane-based chemotherapy at Virginia Commonwealth University (VCU) Health Massey Cancer Center

• Vitamin D serum level <20 ng/mL

Exclusion Criteria:

• Pre-existing diagnosis of neuropathy

• Prior course of taxane-based chemotherapy

• Currently taking prescription Vitamin D (ergocalciferol)

• Inability to converse in English

• Pregnancy

• Chronic kidney disease (stage IV or greater)

• Known hyperparathyroidism

• Hypercalcemia